Durgical
EN
Open the app

Endocrine side effects of immune checkpoint inhibitors

  • Diagnostic approach

Cancer immunotherapy can turn the immune system on the thyroid, pituitary, pancreas or adrenals. The damage lasts, but replacing hormones lets treatment go on.

Updated

See it in 3D: Pituitary gland · Thyroid gland · Pancreas · Left adrenal gland

What it is

Immune checkpoint inhibitors (anti-CTLA-4 such as ipilimumab, anti-PD-1 such as nivolumab and pembrolizumab, and anti-PD-L1) release the brakes on T cells so they attack tumours, and sometimes the patient's own glands. Endocrine immune-related adverse events are among the most frequent. Thyroiditis (mainly with PD-1/PD-L1 blockers) is the commonest; hypophysitis is typical of CTLA-4 blockers and combination therapy; insulin-deficient diabetes, primary adrenal insufficiency and hypoparathyroidism are rare but dangerous. Unlike most immune side effects, endocrine damage is usually permanent and is managed with hormone replacement rather than high-dose glucocorticoids, so immunotherapy can usually continue.

What to know

  • Thyroid disease is the most common endocrine adverse event, mostly with PD-1/PD-L1 blockers: painless destructive thyroiditis with a short thyrotoxic phase, then hypothyroidism that is often permanent.
  • The thyrotoxic phase is destructive, not overproduction: it is treated with a beta-blocker if symptomatic, never with antithyroid drugs; Graves disease is rare.
  • Hypophysitis is typical of CTLA-4 blockade and combination therapy, usually in the first months; it presents with headache and fatigue, and ACTH deficiency (central adrenal insufficiency) is the most important deficit.
  • ACTH deficiency after checkpoint inhibitors is almost always permanent; TSH and gonadotropin deficits may recover; diabetes insipidus is rare, unlike in other forms of hypophysitis.
  • Hypophysitis from PD-1 blockers often causes isolated ACTH deficiency with a normal-looking pituitary on MRI.
  • Checkpoint-inhibitor diabetes is rare but sudden: insulin deficiency, often presenting as diabetic ketoacidosis, very low C-peptide, sometimes with GAD antibodies, and an HbA1c that may be only mildly raised because the onset is so fast; it is permanent.
  • Primary adrenal insufficiency (adrenalitis) is rare: high ACTH, low cortisol and mineralocorticoid deficiency with hyponatraemia and hyperkalaemia.
  • Hypoparathyroidism is very rare and causes severe hypocalcaemia with low PTH.
  • High-dose glucocorticoids do not restore gland function; they are used for hypophysitis only with severe mass effect such as visual loss or intractable headache.
  • Immunotherapy is usually continued once replacement is in place; it is held only during an acute crisis until the patient is stable.

Step-by-step approach

  1. Before the first cycle: TSH, free T4, glucose, electrolytes and a morning cortisol, as a baseline.
  2. Before each cycle: TSH with free T4 and glucose; teach the patient the warning symptoms.
  3. Low TSH with high free T4 → thyroiditis: beta-blocker for symptoms, repeat in a few weeks, expect hypothyroidism.
  4. Low or normal TSH with low free T4 → central hypothyroidism: suspect hypophysitis and check cortisol and ACTH at once.
  5. Low cortisol with low or normal ACTH → hypophysitis; with high ACTH → primary adrenal failure; start hydrocortisone.
  6. Replace glucocorticoid before thyroxine: thyroxine first speeds cortisol use and can trigger adrenal crisis.
  7. High glucose, especially with ketones → treat as new insulin-deficient diabetes or DKA; measure C-peptide.
  8. Unwell, hypotensive, vomiting or confused → treat as adrenal crisis, DKA or severe hypocalcaemia without waiting for results.
  9. Once stable on replacement, continue immunotherapy; give a steroid card and sick-day rules.

Endocrine adverse events of checkpoint inhibitors: pattern, permanence and treatment

DisorderTypical drug classLaboratory patternPermanent?Treatment
Thyroiditis, thyrotoxic phasePD-1/PD-L1Low TSH, high free T4, low uptakeNo, transientBeta-blocker if symptoms; no antithyroid drugs
HypothyroidismPD-1/PD-L1, after thyroiditisHigh TSH, low free T4Usually yesLevothyroxine
HypophysitisCTLA-4 or combinationLow cortisol with low ACTH; often low TSH, LH, FSHACTH deficit yes; others may recoverHydrocortisone first, then other hormones as needed
Insulin-deficient diabetesPD-1/PD-L1High glucose, ketones, very low C-peptideYesInsulin; treat DKA
Primary adrenal insufficiencyPD-1/PD-L1 or combinationLow cortisol, high ACTH, high reninYesHydrocortisone and fludrocortisone
HypoparathyroidismAny, very rareLow calcium, low PTHUsually yesCalcium and active vitamin D

Keys to the differential

  • Fatigue, nausea and low sodium on immunotherapy are easily blamed on the cancer; a morning cortisol and ACTH make the diagnosis of hypophysitis or adrenal failure.
  • Headache in the first months of ipilimumab-containing therapy suggests hypophysitis; a pituitary MRI usually shows enlargement, whereas PD-1-related hypophysitis often does not.
  • A low TSH can mean two opposite things on checkpoint inhibitors: thyroiditis if free T4 is high, central hypothyroidism if free T4 is low.
  • Patients already taking glucocorticoids for another immune side effect have suppressed cortisol tests; their adrenal axis is assessed after the steroids are tapered.

Next step / Initial management

  • Check TSH, free T4 and glucose before every cycle, and morning cortisol with ACTH whenever there is fatigue, hypotension, hyponatraemia or headache.
  • Start hydrocortisone at once for adrenal insufficiency, before levothyroxine; give stress-dose treatment and admit if there is hypotension or vomiting.
  • Treat new hyperglycaemia with ketones as DKA and start insulin; measure C-peptide and diabetes antibodies to confirm insulin deficiency.
  • Continue immunotherapy in most patients once hormone replacement is established, with the oncology team; replacement is usually lifelong.
  • Refer to endocrinology every patient with hypophysitis, adrenal insufficiency, new diabetes or hypoparathyroidism, and thyroiditis that is severe or not following the usual course.

Common traps

  • Checkpoint thyroiditis needs an antithyroid drug: the thyrotoxic phase is destructive release of stored hormone, so antithyroid drugs do nothing and a beta-blocker is enough.
  • High-dose glucocorticoids will rescue the gland: endocrine damage is usually permanent and steroids do not restore function, so replacement is the treatment.
  • A low TSH always means too much thyroid hormone: with hypophysitis TSH is low or normal while free T4 is low, which is central hypothyroidism.
  • Levothyroxine can be started straight away for low free T4: if ACTH is also deficient, thyroxine first can precipitate adrenal crisis, so cortisol is replaced first.
  • Endocrine side effects mean immunotherapy must stop: once hormones are replaced most patients can continue, and stopping would sacrifice cancer control for a manageable deficit.

Test yourself

Think of the answer, then tap the question to see it.

Six weeks into pembrolizumab a man has palpitations, a suppressed TSH and a high free T4, with low radioiodine uptake. What is it and how is it treated?

Painless destructive thyroiditis: a beta-blocker for symptoms, no antithyroid drugs, and repeat tests in a few weeks because hypothyroidism usually follows.

A woman on ipilimumab plus nivolumab has headache, fatigue and sodium of 128 mmol/L; TSH is low-normal and free T4 low. What do you check and give first?

Morning cortisol and ACTH for hypophysitis, and hydrocortisone first, before levothyroxine, because ACTH deficiency is the dangerous deficit.

A patient on a PD-1 inhibitor presents with vomiting, glucose of 480 mg/dL, ketones and an HbA1c of only 7.2%. What is the diagnosis?

Checkpoint-inhibitor insulin-deficient diabetes presenting as DKA; the rapid onset explains the modest HbA1c, C-peptide is very low and insulin is needed for life.

Once a patient with checkpoint-induced hypothyroidism is stable on levothyroxine, should immunotherapy be stopped?

Usually not: endocrine adverse events are managed with replacement, and immunotherapy continues with the oncology team.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of endocrinology

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: Endocrine-Related Adverse Events From Immune Checkpoint Inhibitors (StatPearls (NCBI Bookshelf), 2026); Lymphocytic Hypophysitis (StatPearls (NCBI Bookshelf), 2025); Adrenal Insufficiency (StatPearls (NCBI Bookshelf), 2023).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.